2. 医学
  3. Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolu

Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolu

admin2013-11-30  23
问题     Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolution is based on the idea that the sicker people are, the more freedom they should have to try drugs that are not yet fully tested. For fifty years government policy has been driven by another idea; the fear that insufficiently tested medicines could cause deaths and injuries. The urgent needs of people infected with HIV, the AIDS virus, and the possibility of meeting them with new drugs have created a compelling countervailing force to the continuing concern with safety. As a result, government rules and practices have begun to change. Each step is controversial. But the shift has already gone far beyond AIDS. New ways are emerging for very sick people to try some experimental drugs before they are marketed. People with the most serious forms of heart disease, cancer, emphysema, Alzheimer’ s or Parkinson’ s disease, multiple sclerosis, epilepsy , diabetes, or other grave illnesses can request such drugs through their doctors and are likelier to get them than they would have been four years ago. " We’ ve been too rigid in not making life-saving drugs available to people who otherwise face certain death," says Representative Henry Wax-man, of California, who heads the subcommittee that considers changes in drug-approval policies. "It’ s true of AIDS, but it’ s also true of cancer and other life-threatening diseases. "
    For the first time, desperate patients have become a potent political force for making new medicines available quickly. People with AIDS and their advocates, younger and angrier than most heart-disease or cancer patients, are drawing on two decades of gay activists’ success in organizing to get what they want from politicians. At times they found themselves allied with Reagan Administration deregulators, scientists, industry representatives, FDA staff members, and sympathetic members of Congress. They organized their own clinical trials and searched out promising drugs here and abroad. The result is a familiar Washington story; a crisis—AIDS—helped crystallize an informal coalition for reform.
    AIDS gave new power to old complaints. As early as the 1970s the drug industry and some independent authorities worried that the Food and Drug Administration’ s testing requirements were so demanding that new drugs were being unreasonably delayed. Beginning in 1972, several studies indicated that the United States had lost its lead in marketing new medicines and that breakthrough drugs, those that show new promise in treating serious or life—threatening diseases—had come to be available much sooner in other countries. Two high-level commissions urged the early release of breakthrough drugs. So did the Carter Administration, but the legislation it proposed died in Congress. Complaints were compounded by growing concern that "if we didn’ t streamline policies, red tape would be an obstacle to the development of the biotechnology revolution," as Frank E. Young, who was the head of the FDA from 1984 to 1989, put it in an interview with me.
    Young was a key figure in the overhaul of the FDA’ s policies. A pioneer in biotechnology and a former dean of the University of Rochester’ s medical school, he came to Washington with an agenda and headed the agency for five and a half years—longer than anyone else has since the 1960s. Young took the FDA job to help introduce new medicines created by biotechnology—whose promise he had seen in his own gene-cloning lab and to get experimental medicines to desperately ill people more quickly. He had seen people die waiting for new medicines because " they were in the wrong place at the wrong time," he said. That is now changing.  
During his tenure of office as head of the FDA, Frank E. Young______.
选项 A、had a bitter argument with his colleagues over the overhaul of drug-approval policies
B、played a leading role in reconstructing the FDA’ s policies
C、made some efforts to overhaul drug-approval policies, but failed
D、met many difficulties in releasing breakthrough drugs to the desperately ill patients
答案B
解析 最后一段第一句指出“Young was a key figure in the overhaul of the FDA’s policies”，即Young在FDA的政策修订方面是一个重要人物，选项B正确。
转载请注明原文地址:https://www.kaotiyun.com/show/ftU3777K
本试题收录于： 医学博士外语题库考研分类
0

医学博士外语

考研

相关试题推荐
随机试题
最新回复(0)